Dearborn Partners LLC Decreases Holdings in Stryker Corporation $SYK

Dearborn Partners LLC trimmed its holdings in shares of Stryker Corporation (NYSE:SYK) by 3.8% in the fourth quarter, Holdings Channel reports. The firm owned 80,912 shares of the medical technology company’s stock after selling 3,173 shares during the period. Dearborn Partners LLC’s holdings in Stryker were worth $28,438,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Czech National Bank boosted its position in Stryker by 3.9% in the 4th quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock valued at $31,898,000 after buying an additional 3,366 shares during the last quarter. Davis R M Inc. boosted its position in Stryker by 1.8% in the 3rd quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company’s stock valued at $51,285,000 after buying an additional 2,512 shares during the last quarter. Kepler Cheuvreux Suisse SA purchased a new position in Stryker in the 3rd quarter valued at about $27,952,000. Daymark Wealth Partners LLC boosted its position in Stryker by 436.0% in the 4th quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company’s stock valued at $16,119,000 after buying an additional 37,307 shares during the last quarter. Finally, Wealthcare Advisory Partners LLC boosted its position in Stryker by 265.2% in the 4th quarter. Wealthcare Advisory Partners LLC now owns 9,328 shares of the medical technology company’s stock valued at $3,278,000 after buying an additional 6,774 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on SYK. Leerink Partners decreased their price objective on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research report on Friday. Wells Fargo & Company decreased their price objective on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Robert W. Baird set a $385.00 price objective on shares of Stryker in a research report on Friday, May 1st. Truist Financial reissued a “hold” rating and issued a $330.00 price objective (down from $380.00) on shares of Stryker in a research report on Monday, May 4th. Finally, William Blair reissued an “outperform” rating on shares of Stryker in a research report on Thursday, March 5th. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and a consensus target price of $395.33.

Insider Activity

In other news, VP M Kathryn Fink sold 3,500 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.45, for a total value of $992,075.00. Following the sale, the vice president owned 177 shares in the company, valued at approximately $50,170.65. This represents a 95.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is currently owned by corporate insiders.

Stryker Stock Performance

Shares of Stryker stock opened at $305.71 on Friday. The firm has a market cap of $117.20 billion, a PE ratio of 35.38, a price-to-earnings-growth ratio of 1.93 and a beta of 0.78. The firm’s 50-day simple moving average is $318.43 and its 200-day simple moving average is $345.86. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $404.87.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The company had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter last year, the company posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities analysts forecast that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio is 40.74%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.